Galderma has secured European Union approval for Restylane Shaype for chin augmentation, expanding the indication set for its next-generation HA filler platform. The CE mark follows earlier approvals for cheek and jawline, positioning Shaype as a full-face volumization system designed to compete directly with Allergan's Voluma XC and Juvéderm Volbella.
Regulatory
Galderma Wins EU Nod for Restylane Shaype
CE mark for chin augmentation expands Shaype portfolio and signals next-gen filler positioning.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Chin approval completes Shaype's full-face portfolio and signals U.S. market entry risk.
Restylane Shaype's architecture—higher G-prime and optimized rheology for structural support—targets the growing demand for precision facial anatomy correction. The chin indication matters because it's a high-margin procedure with strong patient demand, especially in markets where jawline definition drives aesthetic consultation volume. EU approval also de-risks Galderma's U.S. market entry timeline; a 510(k) submission is likely imminent.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.